Pharmaxis Announces NDA Filing for Aridol(TM) (Mannitol Bronchial Challenge Test)
A Potential New Tool in the Diagnosis and Assessment of Asthma
“A definitive asthma diagnosis and effective monitoring and management of the disease have been long-standing challenges for doctors and patients with asthma,” said
Brett Charlton MBBS, PhD, Medical Director, Pharmaxis Ltd, added, “Aridol is designed to measure bronchial hyperresponsiveness that corresponds with airway inflammation, an important underlying component of asthma.”
Aridol will be a standardized test kit containing proprietary dry-powder mannitol (a naturally occurring sugar alcohol), prepared for delivery to the lungs using a proprietary hand-held inhaler. The goal of Aridol is to provide physicians and health care professionals with an objective measure of active airway inflammation through an easy-to-use, single-use test for asthma care and assessment in a variety of healthcare settings.
“Upon approval healthcare professionals will have an easy-to-administer bronchial challenge test improving their ability to diagnose and assess patients with asthma,” said
Aridol is approved for sale in
Pharmaxis is an emerging respiratory specialty pharmaceutical company that researches, develops and commercializes new therapies for undertreated respiratory diseases. Its development pipeline includes: Aridol(TM) (mannitol bronchial challenge test) a tool to diagnose and assess asthma; Bronchitol(TM) (mannitol) for Cystic Fibrosis, bronchiectasis, and chronic obstructive pulmonary disease (COPD); PXS25 for the treatment of lung fibrosis; and PXS4159 for asthma. Founded in 1998, Pharmaxis Ltd is headquartered in Frenchs Forest,
SOURCE Pharmaxis, Inc.